Compare ConocoPhillips (COP) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Sana Biotechnology Inc — how do they compare? ConocoPhillips trades at $133.54 (market cap $161.21B), while Sana Biotechnology Inc trades at $2.9 (market cap $836.71M). The key difference: ConocoPhillips is far larger — about 192.7× Sana Biotechnology Inc's market cap, and ConocoPhillips pays a 2.5% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Sana Biotechnology Inc for 23 Days on average.
| COP | SANA | |
|---|---|---|
Market Cap | $161.21B | $836.71M |
Volume | 6,058,403 | 4,507,444 |
Sector | Energy | Health |
52-Week High | $141.22 | $5.92 |
52-Week Low | $85.66 | $2.68 |
Typical Hold Time | 79 Days | 23 Days |
Enterprise Value | $176.81B | $749.96M |
Dividend Yield | 2.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $129.84, up 0.38% on the day, with a bullish technical signal driven by moving averages. The stock shows strong profitability with a net income margin of 14.65% and a P/E of 17.17, while recent earnings beat expectations in Q1 and Q2 2026. A 20-year LNG supply deal with Venture Global, announced October 1, 2026, highlights strategic growth initiatives.
The outlook is positive, supported by a 75% analyst buy rating and a consensus price target of $154.75, implying 19% upside. Risks include geopolitical exposure in the Middle East and oil price volatility, but robust cash flow and shareholder returns provide stability for investors.
SANA Biotechnology trades at $2.72, down 1.09% today, showing bearish technical signals with negative moving averages but oversold RSI readings. The company reported no revenue in 2025 with substantial losses (-$244.17M net income) and negative cash flow (-$55.33M), though analyst sentiment remains positive with 82% buy ratings. Recent investor conference presentations highlight ongoing clinical development activities.
While analyst consensus is bullish with a $9.50 price target (Defense World, July 30, 2026), SANA faces significant fundamental challenges including negative profitability metrics and cash burn. Investment appeal hinges on clinical pipeline success, with risks including execution challenges and the pre-revenue biotech business model requiring continued financing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
